Genmab A/S (GMAB) Stock Price & Analysis

GMAB$53.63+0.89 +1.69%

$32.98B

Market Cap

—

P/E

37.06

Forward P/E

37

Score

AI Analysis

Snapshot

Genmab A/S doesn’t screen as a clean setup today — Stocklytics 37/100 leaves more to prove. Under the hood: P/E 43.5, plus revenue compounding ~-13% annually over recent years.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

29
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

20
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

63
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Genmab A/S (GMAB) last printed $53.63. Equity value is $32.98B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$1.82B$2.37B$3.03B$5.37B$10.11B$8.42B$14.51B$16.47B$21.53B$3.72B

About

Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.

Genmab A/S (GMAB) Stock Price & Analysis

GMAB price $53.63 +0.89 +1.69%

Ticker
GMAB
Price
$53.63
Change
+0.89 +1.69%
Market cap ?
$32.98B
Forward P/E ?
37.06
Dividend yield ?
0.00%
Beta ?
0.65
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
37
Value
29
Quality
63
Growth
20

Stocklytics score rationale: value 29, quality 63, growth 20.

Fair value

GMAB fair value $85.61. Price $53.63. Price is 37% below fair value.

Below fair value, but more expensive than usual. A smaller discount than on more than 99% of days in the past 5 years.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price.

Fair value blends a 10-year DCF and an earnings multiple: the average of the DCF value and an earnings value from next-twelve-months EPS times 30.0, a blend of the Biotechnology median (23.8) and the stock's own 10-year median (39.3). How we calculate it →

Compare GMAB

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2027-02-16—0.30—1.27B
2026-11-050.560.361.19B1.20B
2026-08-060.540.371.16B1.12B
2026-05-070.090.15896.00M905.77M
2026-02-170.050.461.06B1.07B
2025-11-060.650.481.02B1.01B
2025-08-070.540.39924.81M952.56M
2025-05-080.310.23725.99M755.47M
2025-02-120.570.36895.80M894.71M
2024-11-060.290.35815.16M809.62M
2024-08-080.220.29789.59M732.47M
2024-05-020.160.16598.08M572.03M
2024-02-140.360.34675.34M671.21M
2023-11-070.473.14669.38M642.86M
2023-08-030.302.18613.29M601.13M
2023-05-100.050.65416.08M404.26M
2023-02-220.123.15754.97M681.42M
2022-11-090.531.65535.64M473.49M
2022-08-100.411.55443.98M412.04M
2022-05-110.110.91315.14M300.49M
2022-02-160.175.30399.16M389.00M
2021-11-100.210.11360.41M270.35M
2021-08-110.080.08314.36M353.27M
2021-05-050.270.23249.78M214.32M
2021-02-230.141.28335.62M563.55M
2020-11-040.130.99271.70M459.63M
2020-08-120.760.88822.37M231.81M
2020-05-060.060.06129.82M763.51M
2020-02-190.340.36449.49M430.54M
2019-11-061.260.08152.42M195.69M
2019-08-200.200.27117.59M144.85M
2019-03-310.02—88.87M—
2018-12-310.22—198.32M—
2018-09-300.05—93.53M—
2018-06-300.07—79.34M—
2018-03-310.05—112.55M—
2017-12-310.20—160.31M—
2017-09-30-0.00—51.15M—
2017-06-300.08—118.46M—
2017-03-310.00—36.09M—

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
No data yet.

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 307, holders +26 vs prior quarter. Ownership 16.70%.

HolderSharesChangeChange %Value
PARADIGM BIOCAPITAL ADVISORS LP13.13M5.17M+64.83%360.77M
ORBIS ALLAN GRAY LTD11.37M-1.56M-12.05%312.28M
ALLIANCEBERNSTEIN L.P.8.64M-912.27K-9.55%231.94M
DEERFIELD MANAGEMENT COMPANY, L.P.6.87M4.40M+178.84%188.58M
DEEP TRACK CAPITAL, LP5.65M1.99M+54.23%155.21M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP4.98M00.00%136.67M
BLACKROCK, INC.4.67M134.69K+2.97%128.32M
SOFINNOVA INVESTMENTS, INC.4.05M3.29M+437.74%111.12M
RENAISSANCE TECHNOLOGIES LLC3.52M-896.70K-20.31%96.64M
TWO SIGMA INVESTMENTS, LP3.51M1.17M+49.90%96.33M
HARDING LOEVNER LP3.09M-145.28K-4.50%86.90M
DEEP TRACK CAPITAL, LP3.00M-663.25K-18.11%82.41M
FIRST TRUST ADVISORS LP2.76M295.18K+11.99%75.72M
CITADEL ADVISORS LLC2.48M2.30M+1335.36%68.02M
QUBE RESEARCH & TECHNOLOGIES LTD1.69M1.01M+149.40%46.40M
MORGAN STANLEY1.63M-554.54K-25.38%44.78M
FEDERATED HERMES, INC.1.45M197.79K+15.80%39.81M
GOLDMAN SACHS GROUP INC1.28M347.97K+37.37%35.14M
FRANKLIN TEMPLETON INC1.20M9.78K+0.82%33.04M
PICTET ASSET MANAGEMENT HOLDING SA1.07M-11.54K-1.07%29.28M
UBS GROUP AG961.05K662.92K+222.36%26.40M
PERPETUAL LTD919.05K160.54K+21.17%25.25M
NORTHERN TRUST CORP916.60K-33.93K-3.57%25.18M
MILLENNIUM MANAGEMENT LLC910.60K118.31K+14.93%25.01M
RUSSELL INVESTMENTS GROUP, LTD.883.43K86.36K+10.83%24.27M

Insights · Forecast · Financials · Learn

Stocklytics home · Screener